dc.contributor.author | Balk, Monika | en_US |
dc.contributor.author | Hentschke, Harald | en_US |
dc.contributor.author | Rudolph, Uwe | en_US |
dc.contributor.author | Antkowiak, Bernd | en_US |
dc.contributor.author | Drexler, Berthold | en_US |
dc.date.accessioned | 2017-07-24T18:34:36Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Balk, Monika, Harald Hentschke, Uwe Rudolph, Bernd Antkowiak, and Berthold Drexler. 2017. “Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices.” Scientific Reports 7 (1): 3503. doi:10.1038/s41598-017-03154-5. http://dx.doi.org/10.1038/s41598-017-03154-5. | en |
dc.identifier.issn | | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490867 | |
dc.description.abstract | The benzodiazepine midazolam is widely used in critical care medicine. Midazolam has a clinically active metabolite, 1-hydroxymidazolam. The contribution of 1-hydroxymidazolam to the effects of midazolam is controversial. The aim of the current study was to compare the actions of midazolam and 1-hydroxymidazolam on network activity of cortical neurons. Midazolam depressed neuronal activity at a low concentration of 5 nM. When midazolam concentration was increased, it depressed neuronal discharge rates in a biphasic manner. In comparison, 1-hydroxymidazolam did not depress the cortical network activity at low nanomolar concentrations. Higher concentrations of 1-hydroxymidazolam consistently inhibited neuronal activity. Moreover, midazolam shortened cortical up states at low, but not at high concentrations, while the opposite effect was observed with 1-hydroxymidazolam. The network depressant action of midazolam at low concentrations was absent in slices from GABAA receptor α1(H101R)mutant mice. The α1(H101R)mutation renders α1-subunit containing GABAA receptors insensitive towards benzodiazepines. This GABAA receptor subtype is thought to mediate sedation. As midazolam is more potent than its metabolite 1-hydroxymidazolam, the major clinical effects are thus likely caused by midazolam itself. However, 1-hydroxymidazolam could add to the effects of midazolam, especially after the application of high doses of midazolam, and in case of impaired drug metabolism. | en |
dc.language.iso | en_US | en |
dc.publisher | Nature Publishing Group UK | en |
dc.relation.isversionof | doi:10.1038/s41598-017-03154-5 | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471240/pdf/ | en |
dash.license | LAA | en_US |
dc.title | Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | Scientific Reports | en |
dash.depositing.author | Rudolph, Uwe | en_US |
dc.date.available | 2017-07-24T18:34:36Z | |
dc.identifier.doi | 10.1038/s41598-017-03154-5 | * |
dash.contributor.affiliated | Rudolph, Uwe | |